| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
Acetylcholinesterase (AChE)
(S)-Donepezil targets acetylcholinesterase (AChE), the enzyme responsible for hydrolyzing the neurotransmitter acetylcholine in the synaptic cleft. By inhibiting AChE, it increases acetylcholine levels in the brain, enhancing cholinergic neurotransmission. This mechanism is particularly relevant for the treatment of Alzheimer's disease and other cognitive disorders associated with cholinergic dysfunction. |
|---|---|
| ln Vitro |
In cell-free enzyme assays, (S)-Donepezil acts as a potent and specific inhibitor of AChE. The compound demonstrates high inhibitory activity, consistent with its role as a reversible AChE inhibitor. Its potency is reflected in its ability to effectively reduce the hydrolysis of acetylcholine in biochemical assays, making it a valuable tool for neuropharmacological research. While specific cellular assay data for the (S)-enantiomer alone may be limited, the parent compound donepezil has been extensively studied in cellular models. In these assays, it shows neuroprotective effects against Aβ42 neurotoxicity. It is used to study cholinergic signaling and the effects of AChE inhibition on neuronal function and survival in the context of neurodegenerative diseases.
|
| ln Vivo |
In vivo, (S)-Donepezil is studied in animal models of Alzheimer's disease and other cognitive disorders. Its ability to cross the blood-brain barrier and inhibit brain AChE makes it effective in improving cognitive function in preclinical models. Studies focus on its effects on memory, learning, and neurodegeneration.
|
| Enzyme Assay |
Cell-free enzyme inhibition assays for (S)-Donepezil are performed using purified AChE enzyme. The enzyme is incubated with varying concentrations of the compound and a chromogenic substrate, such as acetylthiocholine. The rate of substrate hydrolysis is measured spectrophotometrically, and the IC50 value is determined from the inhibition curve.
|
| Cell Assay |
Cellular assays for (S)-Donepezil are conducted using neuronal cell lines or primary neurons. Cells are treated with the compound, and markers of cholinergic function, such as acetylcholine levels, are measured. Neuroprotective effects against amyloid-beta toxicity can be assessed in appropriate cell models.
|
| Animal Protocol |
In vivo animal studies for (S)-Donepezil are conducted in rodent models of cognitive impairment. The compound is administered orally or via injection, and its effects on memory and learning are assessed using behavioral tests such as the Morris water maze. Brain AChE inhibition and acetylcholine levels are also measured.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of (S)-Donepezil are consistent with those of a central nervous system drug. It is orally bioavailable and able to cross the blood-brain barrier. The compound is metabolized in the liver, and its half-life supports once-daily dosing. Detailed PK parameters are well-characterized for the parent compound donepezil.
|
| Toxicity/Toxicokinetics |
Preclinical toxicity data for (S)-Donepezil are aligned with the safety profile of donepezil. It is generally well-tolerated at therapeutic doses, with common side effects related to cholinergic stimulation. Comprehensive toxicological studies have been conducted for the racemic mixture.
|
| References |
|
| Additional Infomation |
(S)-Donepezil is a 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one with the S configuration. It is the conjugate base of (S)-donepezil (1+) and the enantiomer of (R)-donepezil.
(S)-Donepezil is a research compound used to study the pharmacology of AChE inhibition and the treatment of Alzheimer's disease. Its enantiomeric purity makes it a valuable tool for understanding stereospecific interactions with AChE and potential differences in pharmacokinetics and pharmacodynamics compared to the racemate. It is not approved for clinical use as a single enantiomer. |
| Molecular Formula |
C24H29NO3
|
|---|---|
| Molecular Weight |
379.49
|
| Exact Mass |
379.214
|
| Elemental Analysis |
C, 75.96; H, 7.70; N, 3.69; O, 12.65
|
| CAS # |
142057-80-5
|
| Related CAS # |
Donepezil;120014-06-4
|
| PubChem CID |
969462
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
527.9±50.0 °C at 760 mmHg
|
| Melting Point |
206.72° C
|
| Flash Point |
273.1±30.1 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.578
|
| LogP |
4.71
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
28
|
| Complexity |
510
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
COC1=C(C=C2C(=C1)C[C@@H](C2=O)CC3CCN(CC3)CC4=CC=CC=C4)OC
|
| InChi Key |
ADEBPBSSDYVVLD-FQEVSTJZSA-N
|
| InChi Code |
InChI=1S/C24H29NO3/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18/h3-7,14-15,17,20H,8-13,16H2,1-2H3/t20-/m0/s1
|
| Chemical Name |
(2S)-2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (263.51 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.59 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.59 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.59 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6351 mL | 13.1756 mL | 26.3512 mL | |
| 5 mM | 0.5270 mL | 2.6351 mL | 5.2702 mL | |
| 10 mM | 0.2635 mL | 1.3176 mL | 2.6351 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
